Notteroy, Norway

Maaike Maria Barbara Wilhelmina Dooper


 

Average Co-Inventor Count = 3.0

ph-index = 1

Forward Citations = 3(Granted Patents)


Company Filing History:


Years Active: 2015-2017

Loading Chart...
Loading Chart...
2 patents (USPTO):Explore Patents

Title: Maaike Maria Barbara Wilhelmina Dooper: Innovator in Allergy Treatment

Introduction

Maaike Maria Barbara Wilhelmina Dooper is a notable inventor based in Notteroy, Norway. She has made significant contributions to the field of allergy treatment through her innovative research and development of fusion proteins. With a total of 2 patents, her work is paving the way for new therapeutic approaches to managing allergic diseases.

Latest Patents

Maaike's latest patents focus on the development of fusion proteins for the treatment of allergic diseases. The first patent describes a fusion protein that comprises a first peptide, which is an allergen, and a second peptide that serves as a targeting unit. This targeting unit is a FGL-2 C-terminal peptide according to SEQ ID no 1. The invention outlines the uses of this fusion protein as a vaccine for treating allergies, including shrimp, peanut, or mite allergies. The second patent also details a similar fusion protein aimed specifically at treating shrimp allergy, along with a vaccine composition and methods for producing such fusion proteins.

Career Highlights

Maaike is currently associated with Veterinaerinstituttet, where she continues her research in allergy treatment. Her work is characterized by a strong focus on innovative solutions that address pressing health issues related to allergies.

Collaborations

Maaike collaborates with esteemed colleagues such as Bjarne Bogen and Heidi Ragnhild Myrset. These partnerships enhance her research efforts and contribute to the advancement of her projects.

Conclusion

Maaike Maria Barbara Wilhelmina Dooper is a pioneering inventor whose work in fusion proteins is making a significant impact in the field of allergy treatment. Her innovative patents and collaborations are essential in the ongoing fight against allergic diseases.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…